<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>14</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="epublish">
        <Year>2020</Year>
        <Month>10</Month>
        <Day>07</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Early Normalization of Free Light Chains Predicts Better Outcomes in Patients with Multiple Myeloma</title>
    <FirstPage>226</FirstPage>
    <LastPage>231</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Rony</FirstName>
        <LastName>Benson</LastName>
        <affiliation locale="en_US">Department of Medical Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, India</affiliation>
      </Author>
      <Author>
        <FirstName>Sreejith</FirstName>
        <LastName>Nair</LastName>
        <affiliation locale="en_US">Department of Medical Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, India</affiliation>
      </Author>
      <Author>
        <FirstName>Geetha</FirstName>
        <LastName>Narayanan</LastName>
        <affiliation locale="en_US">Department of Medical Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, India</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2019</Year>
        <Month>10</Month>
        <Day>25</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2020</Year>
        <Month>05</Month>
        <Day>04</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: The half-life of free light chain is short and can be used as an early marker for tumor response
in patients with multiple myeloma [MM]. This prospective study is aimed at evaluating whether early light chain
response can predict response to treatment in patients with MM.
&#xD;

Materials and Methods: Thirty six patients with a diagnosis of MM and with an abnormal to normal light chain ratio of &gt; 10 were included in this study.
&#xD;

Results: The median age at presentation was 56 years. Fourteen patients had lambda light chain disease, whereas 22 patients had kappa light chain disease. Twenty-four patients [66.6%] had reduction of abnormal to normal light chain ratio to &lt; 10 after 2 cycles, of whom 15 [62.5%] achieved a CR or VGPR after 6 cycles. Among 12 patients who did not have reduction of abnormal to normal light chain ratio to &lt; 10, only 1 patient achieved CR while 11 patients [91.6%] achieved a PR or less[Fishers exact p=0.004]. Median follow-up was 13 months. Median progression-free survival for the entire cohort was 15 months. One-year Progression-Free Survival was 77% vs 57.1%, [p= 0.008], respectively for patients with early normalization and those who did not show early normalization.
&#xD;

Conclusion: Early light chain response after 2 cycles of chemotherapy is a good predictor for treatment response in patients with MM treated with bortezomib based chemotherapy. Treatment intensification based on early light chain response merits further evaluation in a prospective trial</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1199</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1199/863</pdf_url>
  </Article>
</Articles>
